MacroGenics Inc
$ 3.46
1.47%
17 Apr - close price
- Market Cap 216,740,000 USD
- Current Price $ 3.46
- High / Low $ 3.54 / 3.42
- Stock P/E N/A
- Book Value 0.88
- EPS -1.14
- Next Earning Report 2026-05-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.18 %
- ROE -0.87 %
- 52 Week High 3.88
- 52 Week Low 1.19
About
MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapies to treat cancer in the United States. The company is headquartered in Rockville, Maryland.
Analyst Target Price
$4.80
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-19 | 2025-11-12 | 2025-08-14 | 2025-05-07 | 2025-03-05 | 2024-11-05 | 2024-08-06 | 2024-05-09 | 2024-03-07 | 2023-11-06 | 2023-08-09 | 2023-05-09 |
| Reported EPS | -0.22 | 0.27 | -0.57 | -0.65 | -0.818 | 0.9 | -0.89 | -0.84 | -0.75 | 0.28 | -0.69 | -0.61 |
| Estimated EPS | -0.2696 | -0.41 | -0.46 | -0.69 | -0.59 | 0.21 | -0.59 | -0.64 | -0.15 | -0.1 | -0.52 | 0.45 |
| Surprise | 0.0496 | 0.68 | -0.11 | 0.04 | -0.228 | 0.69 | -0.3 | -0.2 | -0.6 | 0.38 | -0.17 | -1.06 |
| Surprise Percentage | 18.3976% | 165.8537% | -23.913% | 5.7971% | -38.6441% | 328.5714% | -50.8475% | -31.25% | -400% | 380% | -32.6923% | -235.5556% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-12 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.5 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MGNX
2026-04-14 06:40:10
The article reports that the price target for MacroGenics (MGNX) has been increased by 11.11% to 4.08. This financial update indicates a more optimistic outlook for the company's stock value.
2026-04-12 14:39:13
The article reports that MacroGenics (MGNX) has seen its price target increased by 11.11% to $4.08. MacroGenics is a biotechnology company focused on developing therapies for cancer and autoimmune diseases. This update reflects an adjustment in analyst estimations for the company's stock.
2026-04-11 17:10:28
This article reports that MacroGenics (MGNX) has seen its price target increased by 11.11%, bringing it to $4.08. MacroGenics is a biotechnology company focused on developing therapies for cancer and autoimmune diseases. The price target adjustment indicates a revised outlook on the stock's future performance.
2026-04-11 06:40:10
JPMorgan Chase & Co. significantly increased its stake in MacroGenics, Inc. by 64.1% in the third quarter, acquiring 295,108 additional shares to hold a total of 755,245 shares valued at approximately $1.27 million. MacroGenics (NASDAQ:MGNX) reported better-than-expected earnings and revenue in its latest quarter but remains unprofitable. The biopharmaceutical company has a consensus "Hold" rating from analysts with an average price target of $3.80, and currently trades near its 52-week high of $3.54.
2026-04-10 11:39:13
B. Riley has upgraded MacroGenics (MGNX) from a "Neutral" to a "Buy" rating and significantly increased its price target from $3 to $9. This upgrade follows news that the FDA lifted a partial clinical hold on MacroGenics’ gynecological cancer treatment trial for lorigerlimab. MacroGenics is a biopharmaceutical company focused on developing monoclonal antibody-based therapeutics for cancer.
2026-04-10 04:39:35
MacroGenics announced that the FDA has lifted the partial clinical hold on its dose expansion study of vobramumab, the company's lead product candidate. The hold was originally implemented due to safety concerns involving patients who had previously been treated with an anti-PD-1/PD-L1 therapy. This removal allows MacroGenics to proceed with expanding the study as planned.
